Intellia Therapeutics (NTLA) Reports Q4 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
March 14, 2017 7:15 AM EDTFirst to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levelsFurther established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic developmentExecuted partnering deal with Regeneron Pharmaceuticals, and continued to advance Intellias partnership with Novartis, to support Intellias emerging pipeline with six distinct programs in active research and development, spanning multiple types of genome editingContinued to deploy a diversified approach to maximize CRISPR potential, including pursuing CRISPR... More
